Literature DB >> 24438740

A retrospective analysis of securing autologous split-thickness skin grafts with negative pressure wound therapy in paediatric burn patients.

Michael Hoeller1, Michael Valentin Schintler2, Klaus Pfurtscheller3, Lars-Peter Kamolz2, Norbert Tripolt4, Marija Trop3.   

Abstract

BACKGROUND AND AIM: Deep dermal and full-thickness burn wounds are excised and grafted with split-thickness skin grafts. Especially in less compliant patients such as young children, conventional fixing methods can often be ineffective due to high mobility rates in this age group. The aim of this retrospective single-centre study was to give an overview of our experience in the fixation of autologous split-thickness skin grafts (ASTSGs) on burn wounds by negative pressure wound therapy (NPWT) in paediatric patients.
METHODS: A retrospective analysis describing 53 paediatric patients with burns or burn-related injuries who were treated as 60 individual cases were conducted. All patients received ASTSGs secured by NPWT.
RESULTS: Of the individual cases, 60 cases with a mean age of 8±6 years (the youngest was 3 months, the eldest was 24 years old) were treated in a single procedure with ASTSG and NPWT. Total burn surface area (TBSA) was, median (med) 4.5% (3.0-12.0%). The TBSA of deep dermal thickness to full-thickness (IIb-III°) burns was med 4.0% (2.0-6.0%). The TBSA treated with ASTSG and NPWT was med 3.5% (2.0-6.0%). Take rate was, med 96% (90-99%) with a total range of 70-100%. The only significant correlation that could be found was between the grafted TBSA and the take rate. The smaller the grafted TBSA the better the take rate resulted, as expected. In three cases, major complications were noted.
CONCLUSION: To sum up our experience, the NPWT system has developed itself to be a constant, well-implemented and useful tool in securing ASTSGs to the wound bed. The main advantage of the technique is a much higher mobility of the patient compared to conventional fixation methods. The high compliance rate of an often challenging group of patients such as children recompenses possible higher costs compared to conventional fixation methods.
Copyright © 2013 Elsevier Ltd and ISBI. All rights reserved.

Entities:  

Keywords:  Autologous split-thickness skin graft; Mobility; Negative pressure wound therapy; Treatment of paediatric burns

Mesh:

Year:  2014        PMID: 24438740     DOI: 10.1016/j.burns.2013.12.007

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  5 in total

Review 1.  Negative-Pressure Wound Therapy in Infants and Children: A Population-Based Study.

Authors:  Katherine B Santosa; Matt Keller; Margaret A Olsen; Alexandra M Keane; Erika D Sears; Alison K Snyder-Warwick
Journal:  J Surg Res       Date:  2018-11-30       Impact factor: 2.192

2.  Severe complications after negative pressure wound therapy in burned wounds: two case reports.

Authors:  Haitao Ren; Yuan Li
Journal:  Ther Clin Risk Manag       Date:  2014-07-01       Impact factor: 2.423

3.  "Elephant-trunk" negative pressure wound therapy for fixing artificial dermis with basic fibroblast growth factor for critical limb ischemia.

Authors:  Yosuke Niimi; Kan Nakamoto; Wataru Kamei; Nagisa Osa; Keijiro Hori; Hiroyuki Sakurai
Journal:  Regen Ther       Date:  2021-09-04       Impact factor: 3.419

4.  The SILKIE (Skin graftIng Low friKtIon Environment) study: a non-randomised proof-of-concept and feasibility study on the impact of low-friction nursing environment on skin grafting success rates in adult and paediatric burns.

Authors:  Linda Hollén; Rosemary Greenwood; Rebecca Kandiyali; Jenny Ingram; Chris Foy; Susan George; Sandra Mulligan; Francesca Spickett-Jones; Simon Booth; Anthony Sack; Alan Emond; Ken Dunn; Amber Young
Journal:  BMJ Open       Date:  2018-06-14       Impact factor: 2.692

5.  Negative-pressure wound therapy for fixing full-thickness skin graft on the thumb.

Authors:  Yosuke Niimi; Hiroshi Ito; Hiroyuki Sakurai
Journal:  JPRAS Open       Date:  2018-08-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.